Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Disease area: Thoracic oncology

Abstract

BACKGROUND:Epidermal growth factor receptor (EGFR) overexpression is observed in significant proportions of non-small cell lung carcinomas (NSCLC). Furthermore, overactivation of vascular endothelial growth factor (VEGF) leads to increased angiogenesis implicated as an important factor in vascularization of those tumors.PATIENTS AND METHODS:Using tissue microarray technology, forty-paraffin (n = 40) embedded, histologically confirmed primary NSCLCs were cored and re-embedded into a recipient block. Immunohistochemistry was performed for the determination of EGFR and VEGF protein levels which were evaluated by the performance of computerized image analysis. EGFR gene amplification was studied by chromogenic in situ hybridization based on the use of EGFR gene and chromosome 7 centromeric probes.RESULTS:EGFR overexpression was observed in 23/40 (57.5%) cases and was correlated to the stage of the tumors (p = 0.001), whereas VEGF was overexpressed in 35/40 (87.5%) cases and was correlated to the stage of the tumors (p = 0.005) and to the smoking history of the patients (p = 0.016). Statistical significance was assessed comparing the protein levels of EGFR and VEGF (p = 0.043, k = 0.846). EGFR gene amplification was identified in 2/40 (5%) cases demonstrating no association to its overall protein levels (p = 0.241).CONCLUSIONS:A significant subset of NSCLC is characterized by EGFR and VEGF simultaneous overexpression and maybe this is the eligible target group for the application of combined anti-EGFR/VEGF targeted therapies at the basis of genetic deregulation .

Rating:

Share or cite this content

Citations should be made in the following way:
A. Stamatelopoulos, E. Tsiambas, I. Gakidis, P. Michos, D. Bouros, N. Atzoulatos (Athens, Alexandroupolis, Greece). Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays. Eur Respir J 2014; 44: Suppl. 58, 518

Member's Comments

No comment yet.

Related content which might interest you: Significance of expression of TGF-β in pulmonary metastasis in non-small cell lung cancer tissues Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level? Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Abnormal abundance of senescent fibroblasts in the tumor stroma of non-small cell lung cancer patients Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer Year: 2013 A tissue microarray analysis on the role of chromosome 7 multiplication regarding the EGFR expression in non-small cell lung carcinomas Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016 CD33+CD14-CD11b+CD66b+CD15+VEGFR-1hi myeloid derived suppressor cells and their clinical relevance in non-small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 beta-F1-ATPase expression as a prognostic factor for resected non-small cell lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Role of hypoxia in epithelial-to-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Comprehensive evaluation of nuclear factor-κΒ expression patterns in non-small cell lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign bronchial mucosa of smokers with and without NSCLC Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer Year: 2013 A requirement for IKKa in lung adenocarcinoma Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Clinical significance of erythropoietin (Epo) and its receptor (EpoR) in non-small cell lung carcinoma Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 The influence of erythropoietin on growth and survival in non-small cell lung cancer cell lines Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Proapoptotic effects of PAI-1 protein on lung and prostate cancer cells Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013 EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 RBM5 overexpression reverses acquired resistance to gefitinib in PC9/AB2 NSCLC cells Source: International Congress 2016 – Late-breaking translational research in lung cancer Year: 2016 The prognostic impact of PD1 and PDL1 expression in non-small cell lung cancer Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Immunohistochemical expression of nuclear factor kappa-B/p65 and cyclooxygenase-2 in non-small cell lung cancer patients: Prognostic value and impact on survival Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014